Bausch Health Companies Inc. BHC on Tuesday agreed to indirectly acquire DURECT Corp DRRX, including a novel therapeutic molecule, larsucosterol.Larsucosterol, an endogenous sulfated oxysterol and an epigenetic modulator, has demonstrated promising results for alcoholic hepatitis (AH) in Phase 2 trials.Alcoholic hepatitis is a severe liver inflammation caused by excessive alcohol consumption. It is characterized by the rapid onset of jaundice and liver enlargement.Bausch Health’s hepatology development and ...